Abbott, CamDiab and Ypsomed have entered a partnership to develop and market an integrated automated insulin delivery (AID) system to help patients manage their diabetes round-the-clock.

The alliance will focus on European countries in the initial stage.

The new AID system is being developed to integrate the FreeStyle Libre 3 sensor of Abbott with CamDiab’s CamAPS FX mobile app, which connects with the mylife YpsoPump of Ypsomed, to offer a smart, automated approach for delivering insulin based on real-time glucose readings.

The FreeStyle Libre 3 sensor is claimed to be the world’s smallest and most precise continuous glucose monitoring sensor, offering readings minute by minute.

Designed to continuously screen the glucose levels of an individual, this new connected, smart wearable solution can automatically regulate and offer the correct quantity of insulin at the appropriate time, eliminating guesswork in insulin dosing.

Ypsomed CEO Simon Michel said: “When combined our mylife YpsoPump with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The companies plan to conclude the development of the new system by the end of the year, followed by making it commercially available.

Abbott diabetes care business senior vice-president Jared Watkin said: “Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders.

“We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”

Earlier this month, the US Food and Drug Administration approved Abbott’s Aveir single-chamber (VR) leadless pacemaker for treating patients with slow heart rhythms.